Neuregulin 1 type III improves peripheral nerve myelination in a mouse model of congenital hypomyelinating neuropathy. (10th December 2018)

• Record Type: Journal Article
• Authors: Belin, Sophie; Ornaghi, Francesca; Shackleford, Ghjuvan'Ghjacumu; Wang, Jie; Scapin, Cristina; Lopez-Anido, Camila; Silvestri, Nicholas; Robertson, Neil; Williamson, Courtney; Ishii, Akihiro; Taveggia, Carla; Svaren, John; Bansal, Rashmi; Schwab, Markus H; Nave, Klaus; Fratta, Pietro; D'Antonio, Maurizio; Poitelon, Yannick; Feltri, M Laura; Wrabetz, Lawrence
• Is Part Of: Human molecular genetics. Volume 28:Number 8(2019)
• Page Start: 1260
• Page End: 1273
• Publication Date: 2018-12-10
• Subjects: Human molecular genetics -- Periodicals; Human chromosome abnormalities -- Periodicals; 572.8
• DOI: 10.1093/hmg/ddy420
• Languages: English
• ISSNs: 0964-6906

Abstract

Abstract: Myelin sheath thickness is precisely regulated and essential for rapid propagation of action potentials along myelinated axons. In the peripheral nervous system, extrinsic signals from the axonal protein neuregulin 1 (NRG1) type III regulate Schwann cell fate and myelination. Here we ask if modulating NRG1 type III levels in neurons would restore myelination in a model of congenital hypomyelinating neuropathy (CHN). Using a mouse model of CHN, we improved the myelination defects by early overexpression of NRG1 type III. Surprisingly, the improvement was independent from the upregulation of Egr2 or essential myelin genes. Rather, we observed the activation of MAPK/ERK and other myelin genes such as peripheral myelin protein 2 and oligodendrocyte myelin glycoprotein. We also confirmed that the permanent activation of MAPK/ERK in Schwann cells has detrimental effects on myelination. Our findings demonstrate that the modulation of axon-to-glial NRG1 type III signaling has beneficial effects and improves myelination defects during development in a model of CHN.